Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study
Journal of the American Academy of Dermatology · 2026-10 · 95 (4) · 1109-1112
DOI: 10.1016/j.jaad.2026.05.048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-10. Verfasst von Jennifer Soung und 13 weiteren Autor:innen. Beteiligte Einrichtung: Southern California Clinical Research, Santa Ana and Harbor University of California Los Angeles, Torrance, California. Electronic address: doctorsou…. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson Innovative Medicine, Johnson and Johnson.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Southern California Clinical Research, Santa Ana and Harbor University of California Los Angeles, Torrance, California. Electronic address: doctorsoung@gmail.com.
- Department of Dermatology, China-Japan Friendship Hospital, Beijing, China.
- Innovaderm Research, Montréal, Quebec, Canada.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
- Department of Dermatology, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain; Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, Spain.
- Clinical Research Division, Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt/Main, Frankfurt/Main, Germany.
Förderung
- Johnson & Johnson Innovative Medicine
- Johnson and Johnson
Zitieren
APA
Soung, J., Cui, Y., Bissonnette, R., Lebwohl, M. G., González-Cantero, Á., Pinter, A., Rich, P., Prajapati, V. H., Miller-Kassamali, M., Cafone, J., Jiang, J., Li, S., Yang, Y. W., & Pink, A. E. (2026). Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study. Journal of the American Academy of Dermatology, 95(4), 1109-1112. https://doi.org/10.1016/j.jaad.2026.05.048
Vancouver
Soung J, Cui Y, Bissonnette R, Lebwohl MG, González-Cantero Á, Pinter A, et al. Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study. Journal of the American Academy of Dermatology. 2026;95(4):1109-1112. doi:10.1016/j.jaad.2026.05.048
BibTeX
@article{Soung2026,
author = {Soung, Jennifer and Cui, Yong and Bissonnette, Robert and Lebwohl, Mark G and González-Cantero, Álvaro and Pinter, Andreas and Rich, Phoebe and Prajapati, Vimal H and Miller-Kassamali, Megan and Cafone, Joseph and Jiang, Jingzhi and Li, Shu and Yang, Ya-Wen and Pink, Andrew E},
title = {Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {4},
pages = {1109--1112},
doi = {10.1016/j.jaad.2026.05.048}
}
EUVIMED